Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
ID | DOID:9538 |
Name | multiple myeloma |
Definition | A myeloid neoplasm that is located_in the plasma cells in bone marrow. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer hematologic cancer bone marrow cancer myeloid neoplasm multiple myeloma |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00602693 | Phase I | Sirolimus Allopurinol + Cyclophosphamide + Fludarabine | T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer | Completed | USA | 0 |
NCT00720785 | Phase I | Bortezomib | Natural Killer Cells and Bortezomib to Treat Cancer | Recruiting | USA | 0 |
NCT00734877 | Phase III | Cisplatin + Cyclophosphamide + Doxorubicin + Etoposide Bortezomib + Dexamethasone + Melphalan + Thalidomide | UARK 2008-01, Total Therapy 4 - A Phase III Trial for Low Risk Myeloma | Active, not recruiting | USA | 0 |
NCT00881920 | Phase I | CAR.k.28 cells Cyclophosphamide + Fludarabine | Kappa-CD28 T Lymphocytes, Chronic Lymphocytic Leukemia, B-cell Lymphoma or Multiple Myeloma, CHARKALL (CHARKALL) | Recruiting | USA | 0 |
NCT00903968 | Phase Ib/II | Bortezomib + Plerixafor | Combination Plerixafor (AMD3100)and Bortezomib in Relapsed or Relapsed/Refractory Multiple Myeloma | Completed | USA | 0 |
NCT00918333 | Phase Ib/II | Everolimus + Panobinostat | Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma | Completed | USA | 0 |
NCT01028716 | Phase II | Filgrastim + Mycophenolate mofetil + Tacrolimus Cyclophosphamide + Fludarabine | Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies | Recruiting | USA | 0 |
NCT01084252 | Phase Ib/II | Isatuximab Dexamethasone + Isatuximab | Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies | Active, not recruiting | USA | 16 |
NCT01146834 | Phase III | Bortezomib + Filgrastim Bortezomib + Cyclophosphamide + Filgrastim Bortezomib + Cyclophosphamide | Trial of Three Stem Cell Mobilization Regimens for Multiple Myeloma | Completed | USA | 0 |
NCT01163357 | Phase I | Sirolimus Bortezomib + Fludarabine + Melphalan | Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma | Unknown status | USA | 0 |
NCT01177397 | Phase Ib/II | Onatasertib | Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma | Completed | USA | 3 |
NCT01177683 | Phase Ib/II | Bendamustine + Bortezomib + Pegylated liposomal-doxorubicin Filgrastim | Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma | Terminated | USA | 0 |
NCT01208662 | Phase III | Bortezomib + Dexamethasone + Lenalidomide | Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65 (DFCI 10-106) | Active, not recruiting | USA | 0 |
NCT01239368 | Phase I | Th1/Tc1 Immunotherapy Following Stem Cell Transplantation in Multiple Myeloma | Terminated | USA | 0 | |
NCT01241708 | Phase III | Bortezomib | Tandem Auto Stem Cell Transplant With Melphalan Followed by Melphalan and Bortezomib in Patients With Multiple Myeloma ((Mel/MelVel)) | Active, not recruiting | USA | 0 |
NCT01251575 | Phase II | Fludarabine Cyclosporine + Mycophenolate mofetil + Sirolimus | Sirolimus, Cyclosporine, and Mycophenolate Mofetil In Preventing Graft-Versus-Host Disease in Treating Patients With Hematologic Malignancies Undergoing Donor Peripheral Blood Stem Cell Transplant | Completed | USA | 1 |
NCT01287546 | Phase I | Emibetuzumab + Erlotinib Emibetuzumab + Trametinib Emibetuzumab | A Study of LY2875358 in Participants With Advanced Cancer | Completed | USA | 0 |
NCT01301807 | Phase I | Carfilzomib + Panobinostat | Carfilzomib Plus Panobinostat in Relapsed/Refractory Multiple Myeloma (MM) | Active, not recruiting | USA | 0 |
NCT01313897 | Phase II | Bortezomib | UARK 2010-35, A Study of Expanded Natural Killer Cell Therapy for Multiple Myeloma (NK2010-35) | Completed | USA | 0 |
NCT01323751 | Phase Ib/II | Bortezomib + Dexamethasone Ricolinostat | Study of ACY-1215 Alone and in Combination With Bortezomib and Dexamethasone in Multiple Myeloma | Completed | USA | 0 |
NCT01326702 | Phase Ib/II | Veliparib Rituximab Bendamustine | Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors | Completed | USA | 0 |
NCT01345019 | Phase III | Denosumab Zoledronic acid | Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma | Completed | USA | CAN | 27 |
NCT01353625 | Phase I | CC-115 | Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies. | Active, not recruiting | USA | 3 |
NCT01421524 | Phase I | CC-122 | Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma | Active, not recruiting | USA | 4 |
NCT01428492 | Phase I | Afuresertib Bortezomib Dexamethasone | Ph 1b Study to Evaluate GSK2110183 in Combination With Bortezomib and Dexamethasone in Subjects With Multiple Myeloma | Completed | USA | CAN | 3 |
NCT01440582 | Phase I | Bortezomib + Dexamethasone + Lenalidomide + Panobinostat | Combination Therapy of Lenalidomide/Bortezomib/Dexamethasone and Panobinostat in Transplant Eligible New Diagnosed Multiple Myeloma (MM) Patients | Completed | USA | 0 |
NCT01453088 | Phase II | Melphalan Bortezomib | Auto Transplant High Dose Melphalan vs High Dose Melphalan+Bortezomib in Pts With Multiple Myeloma Age 65 Years or Older | Active, not recruiting | USA | 0 |
NCT01453101 | Phase II | Fludarabine + Melphalan Bortezomib | Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma | Completed | USA | 0 |
NCT01456689 | Phase I | Midazolam LGH447 | A Study of Oral LGH447 in Patients With Relapsed and/or Refractory Multiple Myeloma | Completed | USA | 3 |
NCT01470131 | Phase III | Masitinib Bortezomib + Dexamethasone | A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma | Terminated | USA | 1 |
NCT01522872 | Phase Ib/II | Evofosfamide Bortezomib | Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib in Subjects With Relapsed/Refractory Multiple Myeloma | Unknown status | USA | 0 |
NCT01524978 | Phase II | Vemurafenib Cetuximab | A Study of Zelboraf (Vemurafenib) in Patients With BRAF V600 Mutation-Positive Cancers | Completed | USA | 5 |
NCT01526096 | Phase I | Basiliximab Filgrastim Plerixafor Melphalan | Stem Cell Transplantation for Patients With Multiple Myeloma | Active, not recruiting | USA | 0 |
NCT01547806 | Phase II | Filgrastim Plerixafor | Collection of Transplant Stem Cells for Plasma Cell Myeloma | Completed | USA | 0 |
NCT01582295 | Phase I | Cabozantinib | XL184 For Relapsed/Refractory Multiple Myeloma (MM) With Bone Disease | Completed | USA | 0 |
NCT01587703 | Phase I | Molibresib | A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers | Completed | USA | 6 |
NCT01592370 | Phase I | Nivolumab Ipilimumab Lirilumab | Safety Study in Nivolumab Alone and in Combination With Ipilimumab or Lirilumab in Lymphoma and Multiple Myeloma | Active, not recruiting | USA | 5 |
NCT01609816 | Phase Ib/II | Dasatinib | Dasatinib in Treating Patients With Multiple Myeloma, Non-Hodgkin, or Hodgkin Lymphoma Previously Treated With Autologous Stem Cell Transplant | Terminated | USA | 0 |
NCT01668719 | Phase Ib/II | Elotuzumab Bortezomib + Dexamethasone + Lenalidomide | S1211, Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma | Active, not recruiting | USA | 0 |
NCT01672736 | Phase Ib/II | Bortezomib + Dexamethasone + Linsitinib | A Trial of ASP7487 (OSI-906) in Combination With Bortezomib for the Treatment of Relapsed Multiple Myeloma | Terminated | USA | CAN | 0 |
NCT01689987 | Phase I | Cyclophosphamide + Dexamethasone + Hydroxychloroquine + Sirolimus | Hydroxychloroquine, Cyclophosphamide, Dexamethasone, and Sirolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma | Completed | USA | 0 |
NCT01695330 | Phase II | Bortezomib | Subcutaneous (SC) Bortezomib-Regimens for Patients With RR MM Failing Prior IV Bortezomib-Containing Regimens | Terminated | USA | 0 |
NCT01711528 | Phase I | Bortezomib + Dexamethasone + Dinaciclib | Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma | Completed | USA | 0 |
NCT01723020 | Phase I | KRT-232 | A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma | Completed | USA | 2 |
NCT01729091 | Phase Ib/II | Dexamethasone Elotuzumab Filgrastim Melphalan Lenalidomide | Study of Umbilical Cord Blood-derived Natural Killer Cells in Conjunction With High Dose Chemotherapy and Autologous Stem Cell Transplant for Patients With Multiple Myeloma | Recruiting | USA | 0 |
NCT01729338 | Phase II | Bortezomib + Cyclophosphamide + Lenalidomide | Velcade + Cyclophosphamide in Newly Diagnosed Multiple Myeloma | Terminated | USA | 0 |
NCT01734928 | Phase III | Pomalidomide Bortezomib + Dexamethasone | Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma | Active, not recruiting | USA | CAN | 20 |
NCT01794507 | Phase I | Bortezomib + Dexamethasone + Venetoclax | A Study Evaluating ABT-199 in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy | Completed | USA | 2 |
NCT01794520 | Phase I | Venetoclax | Study Evaluating ABT-199 in Subjects With Relapsed or Refractory Multiple Myeloma | Active, not recruiting | USA | 3 |
NCT01822509 | Phase I | Ipilimumab + Nivolumab | Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant | Active, not recruiting | USA | 0 |
NCT01827137 | Phase I | WT1 vaccine Lenalidomide Sargramostim | WT1 Analog Peptide Vaccine in Patients With Multiple Myeloma Following Autologous Stem Cell Transplantation | Active, not recruiting | USA | 0 |
NCT01829971 | Phase I | MRX34 | A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection | Terminated | USA | 1 |
NCT01849783 | Phase II | Bortezomib + Dexamethasone + Melphalan + Thalidomide Aldoxorubicin + Cisplatin + Cyclophosphamide + Dexamethasone + Etoposide | Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma | Terminated | USA | 0 |
NCT01863550 | Phase III | Dexamethasone Lenalidomide Carfilzomib Bortezomib | Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma | Active, not recruiting | USA | 1 |
NCT01866293 | Phase Ib/II | Cabozantinib | Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma | Completed | USA | 0 |
NCT01889420 | Phase I | Dexamethasone + Everolimus + Pomalidomide | Phase I Trial of Everolimus, Pomalidomide and Dexamethasone Patients With Relapsed/Refractory Multiple Myeloma | Terminated | USA | 0 |
NCT01919086 | Phase II | Lenalidomide Bortezomib + Dexamethasone | Response Adapted Therapy With Bortezomib/Dexamethasone Followed by Addition of Lenalidomide in Non Responders as Initial Treatment for Patients With Multiple Myeloma | Active, not recruiting | USA | 0 |
NCT01947140 | Phase Ib/II | Pralatrexate + Romidepsin | Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies (PDX+Romi) | Recruiting | USA | 0 |
NCT01953692 | Phase I | Pembrolizumab | A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013)(KEYNOTE-013) | Completed | 0 | |
NCT01954784 | Phase I | Bortezomib + Cyclosporine + Mycophenolate mofetil Lenalidomide | Lenalidomide After Donor Stem Cell Transplant and Bortezomib in Treating Patients With High Risk Multiple Myeloma | Terminated | USA | 0 |
NCT01955434 | Phase II | Cyclophosphamide + LCL161 | SMAC Mimetic LCL161 Alone or With Cyclophosphamide in Treating Patients With Relapsed or Refractory Multiple Myeloma | Completed | USA | 0 |
NCT01962792 | Phase Ib/II | Carfilzomib + Ibrutinib Dexamethasone | Study of the Bruton's Tyrosine Kinase Inhibitor in Combination With Carfilzomib (Kyprolis), in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma | Completed | USA | CAN | 0 |
NCT01965353 | Phase I | Bortezomib + Dexamethasone + Lenalidomide + Panobinostat | A Phase I Study Of Panobinostat/Lenalidomide/Bortezomib/Dex for Relapsed And Relapsed/Refractory Multiple Myeloma | Active, not recruiting | USA | 0 |
NCT01989598 | Phase II | Trametinib + Uprosertib | Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Relapsed or Refractory Multiple Myeloma | Active, not recruiting | CAN | 0 |
NCT01995708 | Phase I | CT7/MAGE-A3/WT1 mRNA-electroporated LCs | CT7, MAGE-A3, and WT1 mRNA-electroporated Autologous Langerhans-type Dendritic Cells as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation | Active, not recruiting | USA | 0 |
NCT01997840 | Phase Ib/II | Dexamethasone + Pomalidomide + Ricolinostat | ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple Myeloma | Active, not recruiting | USA | CAN | 2 |
NCT01998971 | Phase I | Pomalidomide Bortezomib + Dexamethasone Melphalan Thalidomide Lenalidomide Prednisone Daratumumab Carfilzomib Diphenhydramine Montelukast | A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma | Active, not recruiting | USA | 2 |
NCT02030483 | Phase I | Palbociclib Dexamethasone Lenalidomide | Palbociclib in Combination With Lenalidomide and Dexamethasone for Multiple Myeloma | Terminated | USA | 0 |
NCT02034110 | Phase II | Dabrafenib + Trametinib | Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers | Active, not recruiting | USA | CAN | 12 |
NCT02036502 | Phase I | Dexamethasone Lenalidomide + Pembrolizumab | A Study of Pembrolizumab (MK-3475) in Combination With Lenalidomide and Dexamethasone in Participants With Multiple Myeloma (MK-3475-023/KEYNOTE-023) | Terminated | 0 | |
NCT02057640 | Phase Ib/II | Dexamethasone + Ixazomib + Panobinostat | MLN9708 (Ixazomib) in Combination With Panobinostat and Dexamethasone in Multiple Myeloma | Completed | USA | 0 |
NCT02061761 | Phase Ib/II | Nivolumab + Relatlimab Relatlimab | Safety Study of Anti-LAG-3 in Relapsed or Refractory Hematologic Malignancies | Active, not recruiting | USA | CAN | 0 |
NCT02077959 | Phase Ib/II | Lenalidomide + Pidilizumab | Lenalidomide and Pidilizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma | Completed | USA | 0 |
NCT02086552 | Phase II | Lenalidomide + Sonidegib | Sonidegib and Lenalidomide After Stem Cell Transplant in Treating Patients With Multiple Myeloma | Active, not recruiting | USA | 0 |
NCT02098109 | Phase II | Plerixafor Filgrastim | Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma | Completed | USA | 0 |
NCT02099539 | Phase Ib/II | ALT-803 | A Study of ALT-803 in Patients With Relapsed or Refractory Multiple Myeloma | Unknown status | USA | 0 |
NCT02101944 | Phase I | Carfilzomib + Dexamethasone + Pelareorep | Viral Protein Production After Dexamethasone, Wild-Type Reovirus, and Carfilzomib in Treating Patients With Multiple Myeloma | Recruiting | USA | 0 |
NCT02104427 | Phase II | Burixafor Filgrastim | PD and Safety of TG-0054 Combined With G-CSF in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients | Completed | USA | 0 |
NCT02110563 | Phase I | DCR-MYC | Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or Lymphoma | Terminated | USA | 0 |
NCT02136134 | Phase III | Daratumumab Bortezomib + Dexamethasone | Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma | Active, not recruiting | USA | 14 |
NCT02140840 | Phase II | Trametinib | A Phase II Open-Label, Multiple-Dose, Single Agent Study to Evaluate the Overall Response Rate of Orally Administered Trametinib | Withdrawn | USA | 0 |
NCT02144038 | Phase Ib/II | Alpelisib + LGH447 LGH447 | Study of the Safety and Effectiveness of LGH447 and BYL719 in Patients With Relapsed and Refractory Multiple Myeloma | Completed | USA | 4 |
NCT02157636 | Phase I | CPI-0610 | A Phase 1 Study Evaluating CPI-0610 in Patients With Previously Treated Multiple Myeloma | Completed | 0 | |
NCT02159365 | Phase II | Dexamethasone + Elotuzumab + Lenalidomide | Study of Safety of Elotuzumab Administered Over Approximately 60 Minutes in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed/Refractory Multiple Myeloma Patients | Completed | USA | 0 |
NCT02186834 | Phase Ib/II | Dexamethasone + Pegylated liposomal-doxorubicin + Selinexor | Selinexor (KPT-330) and Pegylated Liposomal Doxorubicin For Relapsed and Refractory Multiple Myeloma | Active, not recruiting | USA | 0 |
NCT02188368 | Phase II | Bortezomib + Carfilzomib + Clarithromycin Pegylated liposomal-doxorubicin + Pomalidomide Pomalidomide | Pomalidomide for Lenalidomide for Failures | Active, not recruiting | USA | 0 |
NCT02189343 | Phase I | Dexamethasone + Pomalidomide + Ricolinostat | Phase 1b Study Evaluating ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Dexamethasone in Relapsed-and-Refractory Multiple Myeloma | Completed | USA | 0 |
NCT02192775 | Phase II | MV-NIS | UARK 2014-21 A Phase II Trial of Oncolytic Virotherapy by Systemic Administration of Edmonston Strain of Measles Virus | Completed | USA | 0 |
NCT02195479 | Phase III | Bortezomib Daratumumab Melphalan | A Study of Combination of Daratumumanb and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma | Active, not recruiting | USA | 23 |
NCT02199665 | Phase I | Carfilzomib + Dexamethasone + Selinexor | Selinexor, Carfilzomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma | Recruiting | USA | 0 |
NCT02204553 | Phase I | Bortezomib + Dexamethasone + Panobinostat | Expanded Treatment Prot of Panobinostat in Combo w/ Bortez and Dex in Pts w/ Relapsed and/or Refractory Multiple Myeloma | No longer available | USA | 0 |
NCT02211014 | Phase I | Acalabrutinib Dexamethasone | An Open-Label, Phase 1b Study of ACP-196 With and Without Dexamethasone in Subjects With Multiple Myeloma | Completed | USA | 1 |
NCT02220608 | Phase I | Bortezomib + Filgrastim | Phase I Study of Bortezomib With G-CSF for Stem Cell Mobilization in Patients With Multiple Myeloma | Completed | USA | 0 |
NCT02223598 | Phase I | CB-5083 CB-5083 + Dexamethasone | A Phase 1 Study Evaluating CB-5083 in Subjects With Lymphoid Hematological Malignancies (CLC-102) | Terminated | USA | CAN | 0 |
NCT02235740 | Phase I | Carfilzomib Afuresertib + Carfilzomib | A Study Conducted in Subjects With Relapsed/Refractory Multiple Myeloma (MM); to Determine Dose of Afuresertib in Combination With Carfilzomib (Part 1) and to Investigate the Safety, Pharmacokinetic and Clinical Activity of the Combination Compared With Carfilzomib Alone (Part 2) | Terminated | USA | 0 |
NCT02252263 | Phase I | Urelumab Lirilumab Elotuzumab | A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma | Completed | USA | 1 |
NCT02254551 | Phase II | Bortezomib + Sonidegib | Safety/Efficacy Study of LDE225 (Sonidegib) Plus Bortezomib in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma | Terminated | USA | 0 |
NCT02283775 | Phase I | Dexamethasone + Isatuximab + Pomalidomide | SAR650984, Pomalidomide and Dexamethasone in Combination in RRMM Patients (PomdeSAR) | Active, not recruiting | USA | 0 |
NCT02289222 | Phase Ib/II | Dexamethasone + Pembrolizumab + Pomalidomide | Anti-PD-1 (MK-3475) and IMiD (Pomalidomide) Combination Immunotherapy in Relapsed/Refractory Multiple Myeloma | Terminated | USA | 0 |
NCT02291848 | Phase I | MultiTAA-specific T cells | Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma (TACTAM) | Recruiting | USA | 0 |
NCT02308280 | Phase II | Bortezomib | Nonmyeloablative Allogeneic Stem Cell Transplant Followed by Bortezomib in High-risk Multiple Myeloma Patients | Active, not recruiting | CAN | 0 |
NCT02328014 | Phase Ib/II | ACP-319 Acalabrutinib | ACP-196 in Combination With ACP-319, for Treatment of B-Cell Malignancies | Active, not recruiting | USA | 0 |
NCT02331368 | Phase II | Lenalidomide Melphalan Pembrolizumab | Phase 2 Multi-center Study of Anti-PD-1 During Lymphopenic State After HDT/ASCT for Multiple Myeloma | Completed | USA | 0 |
NCT02332850 | Phase I | Carfilzomib + Isatuximab | SAR650984 in Combination With Carfilzomib for Treatment of Relapsed or Refractory Multiple Myeloma | Recruiting | USA | 0 |
NCT02334865 | Phase I | Lenalidomide + Montanide ISA 51 + Sargramostim + SurVaxM | SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy | Recruiting | USA | 0 |
NCT02336815 | Phase II | Dexamethasone + Selinexor | Phase 2b Open-Label Single-Arm Selinexor (KPT-330) + Low-Dose Dexamethasone in Patients w/ Multiple Myeloma Quad-refractory to Previous Therapies | Completed | USA | 5 |
NCT02343042 | Phase Ib/II | Bortezomib Dexamethasone + Selinexor Pomalidomide | Phase 1b/2 Study of Selinexor (KPT-330) in Combination w/ Backbone Treatments for Resistant/Refractory Multiple Myeloma | Recruiting | USA | CAN | 0 |
NCT02356159 | Phase Ib/II | Cytarabine + Fludarabine Palifermin Prednisone Filgrastim Methotrexate + Sirolimus + Tacrolimus Doxorubicin + Etoposide + Fludarabine + Vincristine Sulfate Cyclophosphamide + Fludarabine Rituximab | Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation | Recruiting | USA | 0 |
NCT02367196 | Phase I | CC-90002 + Rituximab CC-90002 | A Phase 1, Dose Finding Study of CC-90002 in Subjects With Advanced Solid and Hematologic Cancers | Active, not recruiting | USA | 3 |
NCT02368301 | Phase I | Dexamethasone + Elotuzumab + Lenalidomide | Expanded Access Treatment Protocol CA204-143 | Approved for marketing | USA | 1 |
NCT02372240 | Phase Ib/II | Dexamethasone + VLX1570 | A Study of VLX1570 and Dexamethasone in Myeloma Patients | Terminated | USA | 0 |
NCT02375555 | Phase II | Elotuzumab Bortezomib + Dexamethasone + Lenalidomide | Study of Bortezomib,Lenalidomide,Dexamethasone & Elotuzumab in Newly Diagnosed MM | Active, not recruiting | USA | 0 |
NCT02391480 | Phase I | Mivebresib | A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer | Completed | USA | 0 |
NCT02393248 | Phase Ib/II | Cisplatin + Gemcitabine + Pemigatinib Docetaxel + Pemigatinib Pemigatinib + Retifanlimab Pemigatinib + Trastuzumab Epacadostat + Pembrolizumab | Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101) | Recruiting | USA | 1 |
NCT02400242 | Phase I | Citarinostat Dexamethasone Pomalidomide | Study of ACY-241 Alone and in Combination With Pomalidomide and Dexamethasone in Multiple Myeloma | Active, not recruiting | USA | 4 |
NCT02401295 | Phase I | Celecoxib + Itraconazole + Tretinoin | ATRA, Celecoxib, and Itraconazole as Maintenance | Completed | USA | 0 |
NCT02426723 | Phase I | CWP232291 Dexamethasone + Lenalidomide | Clinical Study of CWP232291 in Relapsed or Refractory Myeloma Patients | Completed | USA | 1 |
NCT02431208 | Phase I | Lenalidomide Atezolizumab | A Study of Atezolizumab (Anti-Programmed Death Ligand 1 [PD-L1] Antibody) Administered With or Without Lenalidomide in Participants With Multiple Myeloma (MM) | Active, not recruiting | USA | 0 |
NCT02440464 | Phase II | Methotrexate + Tacrolimus Ixazomib Fludarabine + Melphalan Bortezomib | Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302) | Active, not recruiting | USA | 0 |
NCT02441686 | Phase II | Bortezomib + Dexamethasone + Lenalidomide | Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma | Active, not recruiting | USA | 0 |
NCT02465060 | Phase II | Erdafitinib Copanlisib Trametinib Crizotinib Sunitinib Sapanisertib Nivolumab AZD4547 Dasatinib Pertuzumab + Trastuzumab Dabrafenib + Trametinib Binimetinib Adavosertib Osimertinib Palbociclib Afatinib Capivasertib Defactinib GSK2636771 Vismodegib Ado-trastuzumab emtansine Larotrectinib Taselisib | Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) | Recruiting | USA | 2 |
NCT02477878 | Phase I | BPX-601 Rimiducid | Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant | Active, not recruiting | USA | 0 |
NCT02504359 | Phase I | Ixazomib Carmustine + Cytarabine + Etoposide + Melphalan Methotrexate + Tacrolimus | Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple Myeloma | Completed | USA | 0 |
NCT02514382 | Phase I | Bortezomib + Dexamethasone + Pelareorep | Wild-Type Reovirus, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma | Active, not recruiting | USA | 0 |
NCT02514668 | Phase I | Isatuximab | A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Isatuximab in Patients With Multiple Myeloma | Active, not recruiting | USA | 2 |
NCT02519452 | Phase I | Daratumumab + rHuPH20 | A Study of Daratumumab With the Addition of Recombinant Human Hyaluronidase (rHuPH20) for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma | Active, not recruiting | USA | 5 |
NCT02548962 | Phase Ib/II | Ibrutinib Dexamethasone + Pomalidomide | Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma | Terminated | USA | 5 |
NCT02568943 | Phase I | Bortezomib + Dexamethasone + Panobinostat | An Expanded Treatment Protocol of Panobinostat in Combination Therapy for Relapsed, and Relapsed and Refractory Multiple Myeloma | No longer available | CAN | 5 |
NCT02569320 | Phase I | AR-42 + Dexamethasone + Pomalidomide | HDAC Inhibitor AR-42 and Pomalidomide in Treating Patients With Relapsed Multiple Myeloma | Suspended | USA | 0 |
NCT02576496 | Phase I | Tinostamustine | Study of EDO-S101, A First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies | Recruiting | USA | 5 |
NCT02576977 | Phase III | Pomalidomide Pembrolizumab Dexamethasone | Study of Pomalidomide and Low Dose Dexamethasone With or Without Pembrolizumab (MK-3475) in Refractory or Relapsed and Refractory Multiple Myeloma (rrMM) (MK-3475-183/KEYNOTE-183) | Terminated | 0 | |
NCT02579824 | Phase I | Milademetan Tosylate | DS-3032b for Relapsed and/or Refractory (RR) Myeloma | Terminated | USA | 0 |
NCT02579863 | Phase III | Pembrolizumab Dexamethasone Lenalidomide | Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185) | Terminated | 0 | |
NCT02603887 | Phase I | Pembrolizumab | Pembrolizumab for Smoldering Multiple Myeloma (SMM) | Active, not recruiting | USA | 0 |
NCT02605356 | Phase Ib/II | Radium Ra 223 dichloride Bortezomib Dexamethasone | Phase 1b/2 Study Testing Radium-223 Dichloride/Bortezomib/Dexamethasone Combination in Relapsed Multiple Myeloma | Withdrawn | USA | CAN | 9 |
NCT02609230 | Phase I | ONC201 | A Dose-Escalation Study of Onc201 Administered Every One or Three Weeks in Advanced Solid Tumors and Multiple Myeloma | Active, not recruiting | USA | 0 |
NCT02612779 | Phase II | Dexamethasone + Elotuzumab + Pomalidomide | A Study of Elotuzumab in Combination With Pomalidomide and Low Dose Dexamethasone (EPd) in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide | Completed | USA | 0 |
NCT02616640 | Phase I | Pomalidomide Dexamethasone Durvalumab | A Study to Determine Dose and Regimen of Durvalumab as Monotherapy or in Combination With Pomalidomide With or Without Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma | Active, not recruiting | USA | CAN | 5 |
NCT02628704 | Phase II | Carfilzomib + Dexamethasone + Selinexor | Selinexor, Carfilzomib, and Dexamethasone Versus Placebo, Carfilzomib, and Dexamethasone in Multiple Myeloma | Withdrawn | USA | 0 |
NCT02633059 | Phase Ib/II | Dexamethasone + Idasanutlin + Ixazomib | Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma | Active, not recruiting | USA | 0 |
NCT02649790 | Phase Ib/II | KPT-8602 | Study of the Safety, Tolerability and Efficacy of KPT-8602 in Patients With Relapsed/Refractory Multiple Myeloma | Active, not recruiting | USA | CAN | 0 |
NCT02654132 | Phase II | Dexamethasone + Pomalidomide Elotuzumab | Trial of Elotuzumab With or Without Pomalidomide and Low-dose Dexamethasone to Treat Refractory and Relapsed and Refractory Multiple Myeloma | Active, not recruiting | USA | CAN | 9 |
NCT02654990 | Phase II | Bortezomib + Dexamethasone + Panobinostat | Panobinostat/Bortezomib/Dexamethasone in Relapsed or Relapsed-and-refractory Multiple Myeloma | Active, not recruiting | USA | CAN | 20 |
NCT02655458 | Phase I | Elotuzumab + Lenalidomide | Elotuzumab in Autologous Stem Cell Transplantation (ASCT) and Lenalidomide Maintenance for Multiple Myeloma | Completed | USA | 0 |
NCT02658396 | Phase I | Bortezomib + GO-203-2C | GO-203-2C + Bortezomib For Relapsed Or Refractory MM | Withdrawn | USA | 0 |
NCT02658929 | Phase I | bb2121 | Study of bb2121 in Multiple Myeloma | Active, not recruiting | USA | 0 |
NCT02666209 | Phase I | Bortezomib + Dexamethasone + Ulocuplumab Dexamethasone + Lenalidomide + Ulocuplumab | Early Patient Access Single Named Patient Program for the Use of Ulocuplumab for the Treatment of Multiple Myeloma | No longer available | USA | 0 |
NCT02675452 | Phase I | AMG 176 | AMG 176 First in Human Trial in Subjects With Relapsed or Refractory Multiple Myeloma and Subjects With Relapsed or Refractory Acute Myeloid Leukemia | Recruiting | USA | CAN | 3 |
NCT02681302 | Phase Ib/II | Ipilimumab + Nivolumab | Check Point Inhibition After Autologous Stem Cell Transplantation in Patients at High Risk of Post Transplant Recurrence (CPIT001) | Recruiting | USA | 0 |
NCT02684617 | Phase I | Dinaciclib + Pembrolizumab | Study of Pembrolizumab (MK-3475) in Combination With Dinaciclib (MK-7965) in Hematologic Malignancies (MK-3475-155) (KEYNOTE-155) | Terminated | 0 | |
NCT02685826 | Phase I | Dexamethasone Durvalumab + Lenalidomide | A Study of Durvalumab in Combination With Lenalidomide With and Without Dexamethasone in Subjects With Newly Diagnosed Multiple Myeloma | Active, not recruiting | USA | CAN | 6 |
NCT02693535 | Phase II | Cobimetinib + Vemurafenib Regorafenib Ipilimumab + Nivolumab Palbociclib Afatinib Talazoparib Pembrolizumab Temsirolimus Pertuzumab + Trastuzumab Crizotinib Abemaciclib Sunitinib Olaparib | TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer | Recruiting | USA | 0 |
NCT02700841 | Phase II | Melphalan + PVX-410 | Enhancing Anti-Myeloma Vaccine Response After Autologous Stem Cell Transplantation | Recruiting | USA | 0 |
NCT02703779 | Phase II | Bortezomib Filgrastim + Plerixafor | Exploratory Trial to Estimate Proportion of Patients With Tumor Cell Contaminated Leukapheresis Products With and Without Bortezomib With In-vivo Purging - Multiple Myeloma (MM) | Active, not recruiting | USA | 0 |
NCT02716805 | Phase I | Durvalumab + Tremelimumab | Phase 1 Study to Assess Safety & Tolerability of Tremelimumab & Durvalumab, Administered With High Dose Chemotherapy and Autologous Stem Cell Transplant | Terminated | USA | 0 |
NCT02718833 | Phase II | Bortezomib + Dexamethasone + Elotuzumab + Panobinostat | A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma | Active, not recruiting | USA | 0 |
NCT02719613 | Phase II | Bortezomib + Dexamethasone + Elotuzumab + Lenalidomide | Continuing Treatment for Subjects Who Have Participated in a Prior Protocol Investigating Elotuzumab | Active, not recruiting | USA | CAN | 1 |
NCT02720510 | Phase II | Panobinostat Bortezomib + Dexamethasone + Lenalidomide | A Trial Evaluating Efficacy & Safety of RVD +/- Panobinostat in Transplant Eligible, Newly Diagnosed Multiple Myeloma (NDMM) | Terminated | USA | 0 |
NCT02722668 | Phase II | Cyclophosphamide + Fludarabine + Mycophenolate mofetil Sirolimus anti-thymocyte globulin | UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep | Recruiting | USA | 0 |
NCT02722941 | Phase II | Panobinostat | Panobinostat (LBH589): Multiple Myeloma - Autologous Hematopoietic Cell Transplantation (HCT) | Active, not recruiting | USA | 0 |
NCT02726581 | Phase III | Elotuzumab Nivolumab Dexamethasone + Pomalidomide | Study of Combinations of Nivolumab, Elotuzumab, Pomalidomide and Dexamethasone in Multiple Myeloma | Active, not recruiting | USA | CAN | 13 |
NCT02727803 | Phase II | anti-thymocyte globulin + Fludarabine + haNK cells + Melphalan anti-thymocyte globulin + Cyclophosphamide + Fludarabine + haNK cells + Rituximab anti-thymocyte globulin + Busulfan + Clofarabine + Fludarabine + haNK cells | Personalized NK Cell Therapy After Chemotherapy and Cord Blood Transplant in Treating Patients With Myelodysplastic Syndrome, Leukemia, Lymphoma or Multiple Myeloma | Recruiting | USA | 0 |
NCT02755597 | Phase III | Bortezomib + Dexamethasone Bortezomib + Dexamethasone + Venetoclax | A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy | Suspended | USA | CAN | 14 |
NCT02757326 | Phase Ib/II | ABC294640 | ABC294640 in Refractory / Relapsed Multiple Myeloma | Terminated | USA | 0 |
NCT02765854 | Phase II | Dexamethasone + Ixazomib + Lenalidomide Dexamethasone + Ixazomib | Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized With NFKB2 Rearrangement | Recruiting | USA | 0 |
NCT02773030 | Phase Ib/II | Iberdomide Dexamethasone + Iberdomide Daratumumab + Dexamethasone + Iberdomide Bortezomib + Dexamethasone + Iberdomide | A Study to Determine Dose and Tolerability of CC-220 Monotherapy, in Combination With Dexamethasone, and in Combination With Dexamethasone and Daratumumab or Bortezomib in Subjects With Relapsed and Refractory Multiple Myeloma (MM) | Recruiting | USA | CAN | 7 |
NCT02780609 | Phase Ib/II | Dexamethasone + Melphalan + Selinexor | Selinexor Plus High-Dose Melphalan (HDM) Before Autologous Hematopoietic Cell Transplantation for Multiple Myeloma | Recruiting | USA | 0 |
NCT02784483 | Phase I | Atezolizumab | Pilot Study Of Anti-Programmed Death Ligand-1 (Anti-PD-L1, Atezolizumab) In Asymptomatic Myeloma | Terminated | USA | 0 |
NCT02786485 | Phase I | Rimiducid BPX-501 | Study of Matched Unrelated Donor T Cell Infusion for Hematologic Malignancies After Allo-HSCT | Withdrawn | 0 | |
NCT02802163 | Phase Ib/II | Carfilzomib + Dexamethasone + Lenalidomide + Panobinostat | Induction Therapy for Multiple Myeloma With Carfilzomib, Lenalidomide,Dexamethasone,Panobinostat | Withdrawn | 0 | |
NCT02807454 | Phase Ib/II | Daratumumab + Dexamethasone + Durvalumab + Pomalidomide Daratumumab + Durvalumab | A Study to Determine the Safety and Efficacy for the Combination of Durvalumab and Daratumumab in Relapsed and Refractory Multiple Myeloma (FUSIONMM-003) | Active, not recruiting | USA | CAN | 7 |
NCT02831686 | Phase I | Dexamethasone + Ixazomib + Selinexor | A Study to Test the Combination of Selinexor (KPT-330), Ixazomib, and Dexamethasone in Patients With Myeloma | Completed | USA | 0 |
NCT02833610 | Phase II | Denosumab | A Study of Denosumab in Multiple Myeloma Patients With Renal Insufficiency | Recruiting | USA | 0 |
NCT02851056 | Phase I | Ad5-survivin-transduced autologous DC vaccine + Filgrastim + PCV13 vaccine | Survivin Vaccine : Multiple Myeloma Autologous Hematopoietic Cell Transplant (HCT) | Suspended | USA | 0 |
NCT02863991 | Phase II | ONC201 | Oral ONC201 in Relapsed/Refractory Multiple Myeloma | Active, not recruiting | USA | 0 |
NCT02874742 | Phase II | Daratumumab Bortezomib + Dexamethasone + Lenalidomide | Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma | Active, not recruiting | USA | 0 |
NCT02880228 | Phase II | Dexamethasone + Lenalidomide + Pembrolizumab | Pembrolizumab, Lenalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma Eligible for Stem Cell Transplant | Completed | USA | 0 |
NCT02890758 | Phase I | ALT-803 | Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803 | Recruiting | USA | 0 |
NCT02899052 | Phase II | Carfilzomib + Dexamethasone + Venetoclax | Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (MM) | Recruiting | USA | 4 |
NCT02906332 | Phase II | Pembrolizumab Dexamethasone | Pembrolizumab + Lenalidomide Post Autologous Stem Cell Transplant (ASCT) in High-risk Multiple Myeloma (MM) | Active, not recruiting | USA | 0 |
NCT02928029 | Phase Ib/II | Bortezomib + Dexamethasone + Radium Ra 223 dichloride | Study Testing Radium-223 Dichloride in Relapsed Multiple Myeloma | Terminated | USA | 2 |
NCT02931110 | Phase I | CBL0137 | Study of IV CBL0137 in Previously Treated Hematological Subjects | Terminated | USA | 0 |
NCT02943473 | Phase II | Ibrutinib | Study on the Effect of Ibrutinib on High Risk Smoldering Multiple Myeloma Patients | Terminated | USA | 0 |
NCT02948283 | Phase 0 | Metformin + Ritonavir | Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia | Completed | USA | 0 |
NCT02951819 | Phase II | Bortezomib + Cyclophosphamide + Daratumumab + Dexamethasone | A Study to Evaluate Dara-CyBorD in Previously Untreated and Relapsed Subjects With Multiple Myeloma | Completed | USA | 0 |
NCT02952573 | Phase II | Dexamethasone + Erdafitinib | Testing JNJ-42756493 In Combination With Dexamethasone in Multiple Myeloma That Came Back After a Period of Improvement | Terminated | CAN | 0 |
NCT02960646 | Phase I | Fludarabine + Melphalan CD45RA-depleted donor lymphocytes Cyclophosphamide Tacrolimus Rituximab | Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies | Recruiting | USA | 0 |
NCT02963493 | Phase II | Dexamethasone + Melflufen | A Study of Melflufen in Combination With Dexamethasone in Relapsed Refractory Multiple Myeloma Patients (HORIZON) | Active, not recruiting | USA | 3 |
NCT02978235 | Phase Ib/II | TAS4464 | A Dose Finding Study Followed by a Safety and Efficacy Study for Patients With Multiple Myeloma or Lymphoma | Terminated | USA | 0 |
NCT02990338 | Phase III | Dexamethasone + Isatuximab + Pomalidomide Dexamethasone + Pomalidomide | Multinational Clinical Study Comparing Isatuximab, Pomalidomide, and Dexamethasone to Pomalidomide and Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma Patients (ICARIA-MM) | Active, not recruiting | USA | CAN | 22 |
NCT02992483 | Phase I | MIK665 | Phase I Study of MIK665, a Mcl-1 Inhibitor, in Patients With Refractory or Relapsed Lymphoma or Multiple Myeloma | Recruiting | USA | 6 |
NCT02998047 | Phase I | Lintuzumab-Ac225 | A Phase I Study of Lintuzumab-Ac225 in Patients With Refractory Multiple Myeloma | Active, not recruiting | USA | 0 |
NCT03000452 | Phase II | Daratumumab + Durvalumab | A Study to Determine the Efficacy of the Combination of Daratumumab (DARA) Plus Durvalumab (DURVA) (D2) in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) (FUSION-MM-005) | Completed | USA | 5 |
NCT03003728 | Phase II | ALT-803 + Elotuzumab + Melphalan | 2015-10: Expanded Natural Killer Cells and Elotuzumab for High-Risk Myeloma Post- Autologous Stem Cell Transplant (ASCT) | Withdrawn | USA | 0 |
NCT03004287 | Phase II | Melphalan Carfilzomib Cisplatin Cyclophosphamide Lenalidomide Dexamethasone Daratumumab Bortezomib Etoposide Doxorubicin Thalidomide | 2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy | Active, not recruiting | USA | 0 |
NCT03015792 | Phase Ib/II | Dexamethasone + Ibrutinib + Lenalidomide | Ibrutinib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Ineligible for Transplant | Suspended | USA | 0 |
NCT03017820 | Phase I | VSV-hIFNbeta-NIS | VSV-hIFNbeta-NIS in Treating Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia, or T-cell Lymphoma | Recruiting | USA | 0 |
NCT03018405 | Phase Ib/II | NKR-2 cells | A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications (THINK) | Recruiting | USA | 1 |
NCT03019666 | Phase I | Allogeneic NAM NK cells Cyclophosphamide + Fludarabine | Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL | Suspended | USA | 0 |
NCT03030261 | Phase II | Melphalan Dexamethasone + Elotuzumab + Pomalidomide | Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma | Recruiting | USA | CAN | 0 |
NCT03031730 | Phase I | Carfilzomib + Dexamethasone + KRT-232 + Lenalidomide | MDM2 Inhibitor AMG-232, Carfilzomib, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma | Recruiting | USA | 0 |
NCT03068351 | Phase I | TEN-010 Daratumumab + TEN-010 | Study of Bromodomain and Extra-Terminal Protein (BET) Inhibitor RO6870810 as Mono- and Combination Therapy in Advanced Multiple Myeloma | Completed | USA | 2 |
NCT03091257 | Phase I | Dabrafenib + Trametinib Dabrafenib Trametinib | A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma | Recruiting | USA | 0 |
NCT03104270 | Phase II | Carfilzomib + Dexamethasone + Elotuzumab + Pomalidomide | Combination Study for High Risk Multiple Myeloma Patients | Active, not recruiting | USA | 0 |
NCT03106428 | Phase I | MEDI7247 | A Multiple Ascending Dose Study of MEDI7247 in Patients With Selected Relapsed/Refractory Hematological Malignancies | Completed | USA | 2 |
NCT03110562 | Phase III | Bortezomib + Dexamethasone + Selinexor Bortezomib + Dexamethasone | Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma (BOSTON) | Active, not recruiting | USA | CAN | 19 |
NCT03110822 | Phase I | Lenalidomide + Methylprednisolone + Ruxolitinib | A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients | Recruiting | USA | 0 |
NCT03111992 | Phase I | LCL161 + Spartalizumab CJM112 + Spartalizumab Spartalizumab | Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple Myeloma | Completed | USA | 3 |
NCT03143985 | Phase I | Pomalidomide + TEW 7197 | TEW-7197 in Combination w/ Pomalidomide in Relapsed or Relapsed and Refractory Multiple Myeloma | Recruiting | USA | 0 |
NCT03145181 | Phase I | JNJ-64007957 | Dose Escalation Study of JNJ-64007957, a Humanized BCMA CD3 DuoBody® Antibody, in Participants With Relapsed or Refractory Multiple Myeloma | Recruiting | USA | 4 |
NCT03151811 | Phase III | Dexamethasone + Pomalidomide Dexamethasone + Melflufen | A Study of Melflufen-dex or Pomalidomide-dex for RRMM Patients Refractory to Lenalidomide (OCEAN) | Active, not recruiting | USA | 20 |
NCT03168100 | Phase II | Bortezomib + Dexamethasone + Lenalidomide Dexamethasone + Elotuzumab + Lenalidomide | 2017-03: A Single-Arm, Open-label Study of Anti-Signaling Lymphocytic Activation Molecule F7 (Anti-SLAMF7) Monoclonal Antibody (mAb) Therapy After Autologous Stem Cell Transplant in Patients With Multiple Myeloma | Withdrawn | USA | 0 |
NCT03168438 | Phase II | NY-ESO-1-c259T NY-ESO-1-c259T + Pembrolizumab | NY-ESO-1-c259T Alone and in Combination With Pembrolizumab for Multiple Myeloma | Terminated | USA | 0 |
NCT03194867 | Phase Ib/II | Cemiplimab + Isatuximab | Isatuximab in Combination With REGN2810 in Relapsed/Refractory Multiple Myeloma (RRMM) Patients | Active, not recruiting | USA | CAN | 8 |
NCT03201250 | Phase Ib/II | Cabozantinib + Carfilzomib + Dexamethasone | Cabozantinib as a Targeted Strategy to Reverse Carfilzomib Resistance in Refractory Multiple Myeloma | Recruiting | USA | 0 |
NCT03215030 | Phase Ib/II | Dexamethasone + TAK-573 TAK-573 | A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-573 in Participants With Refractory Multiple Myeloma (MM) | Recruiting | USA | 0 |
NCT03218683 | Phase I | AZD5991 | Study of AZD5991 in Relapsed or Refractory Haematologic Malignancies. | Recruiting | USA | 0 |
NCT03221634 | Phase II | Daratumumab + Pembrolizumab | Efficacy and Safety Study of Pembrolizumab (MK-3475) in Combination With Daratumumab in Participants With Relapsed Refractory Multiple Myeloma (MK-3475-668/KEYNOTE-668) | Withdrawn | USA | CAN | 4 |
NCT03227432 | Phase II | Dexamethasone + Elotuzumab + Nivolumab + Pomalidomide Elotuzumab + Nivolumab | An Exploratory Study to Evaluate the Combination of Elotuzumab and Nivolumab With and Without Pomalidomide in Relapsed Refractory Multiple Myeloma | Withdrawn | USA | 0 |
NCT03246529 | Phase III | Filgrastim BKT140 + Filgrastim | A Phase III, Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and G-GSF as Compared to Placebo and G-CSF for thE MobilizatioN of HematopoiEtic Stem Cells for Autologous TransplantatIon in SubjectS With MM (GENESIS) | Unknown status | USA | 0 |
NCT03256045 | Phase II | Carfilzomib + Dexamethasone + Panobinostat | Panobinostat, Carfilzomib and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma | Terminated | USA | 0 |
NCT03266692 | Phase I | ACTR087 + SEA-BCMA | Study of ACTR087 in Combination With SEA-BCMA in Subjects With Relapsed or Refractory Multiple Myeloma | Terminated | USA | 0 |
NCT03267888 | Phase I | Pembrolizumab | Pembrolizumab and Radiation Therapy in Patients With Relapsed or Refractory Multiple Myeloma | Recruiting | USA | 0 |
NCT03269136 | Phase I | PF-06863135 | Phase 1 Study Of PF-06863135, A BCMA- CD3 Bispecific Ab, In Relapse/ Refractory Multiple Myeloma | Recruiting | USA | CAN | 1 |
NCT03275103 | Phase I | BFCR4350A | Dose-Escalation Study of BFCR4350A in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM) | Recruiting | USA | CAN | 2 |
NCT03275285 | Phase III | Carfilzomib + Dexamethasone + Isatuximab Carfilzomib + Dexamethasone | Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients (IKEMA) | Active, not recruiting | USA | CAN | 14 |
NCT03287908 | Phase I | AMG 701 | A Phase 1/2 Study of AMG 701 in Subjects With Multiple Myeloma | Active, not recruiting | USA | CAN | 4 |
NCT03288480 | Phase I | Imifoplatin | A Phase 1/2a Dose-Finding Study of PT-112 in Patients With Relapsed or Refractory Multiple Myeloma | Active, not recruiting | USA | 0 |
NCT03288493 | Phase I | P-BCMA-101 CAR-T cells | P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM) | Recruiting | USA | 0 |
NCT03297606 | Phase II | Bosutinib Palbociclib Vismodegib Ipilimumab + Nivolumab Cobimetinib + Vemurafenib Temsirolimus Olaparib Erlotinib Crizotinib Sunitinib Afatinib Dasatinib Pertuzumab + Trastuzumab Axitinib | Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) (CAPTUR) | Recruiting | CAN | 0 |
NCT03309111 | Phase I | GBR1342 | Study of GBR 1342, a CD38/CD3 Bispecific Antibody, in Subjects With Previously Treated Multiple Myeloma | Recruiting | USA | 0 |
NCT03314181 | Phase II | Bortezomib + Daratumumab + Dexamethasone + Venetoclax Daratumumab + Dexamethasone Daratumumab + Dexamethasone + Venetoclax | A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Subjects With Relapsed or Refractory Multiple Myeloma | Recruiting | USA | CAN | 5 |
NCT03315026 | Phase II | Siltuximab | Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis | Active, not recruiting | USA | 0 |
NCT03319667 | Phase III | Bortezomib + Dexamethasone + Lenalidomide Dexamethasone + Isatuximab + Lenalidomide Bortezomib + Dexamethasone + Isatuximab + Lenalidomide | Clinical Benefit of SAR650984, Bortezomib, Lenalidomide and Dexamethasone Combination in NDMM Patients Not Eligible for Transplant (IMROZ) | Active, not recruiting | USA | 20 |
NCT03333746 | Phase II | Lenalidomide + Nivolumab | Lenalidomide and Nivolumab in Treating Patients With Relapsed or Refractory Multiple Myeloma | Terminated | USA | 0 |
NCT03338972 | Phase I | Cyclophosphamide + Fludarabine Anti-BCMA CAR T Cells | Immunotherapy With BCMA CAR-T Cells in Treating Patients With BCMA Positive Relapsed or Refractory Multiple Myeloma | Recruiting | USA | 0 |
NCT03346135 | Phase II | Melphalan Daratumumab | Daratumumab After Stem Cell Transplant in Treating Patients With Multiple Myeloma | Recruiting | USA | 0 |
NCT03357952 | Phase I | Daratumumab + JNJ-63723283 | A Study of JNJ-63723283, an Anti-programmed Death-1 Monoclonal Antibody, Administered in Combination With Daratumumab, Compared With Daratumumab Alone in Participants With Relapsed or Refractory Multiple Myeloma | Active, not recruiting | 3 | |
NCT03361306 | Phase II | Carfilzomib + Dexamethasone + Elotuzumab + Lenalidomide | LCI-HEM-MYE-CRD-002: Carfilzomib-Revlimid-Dexamethasone-Elotuzumab in Relapsed/Refractory Multiple M | Recruiting | USA | 0 |
NCT03361748 | Phase II | bb2121 | Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma (KarMMa) (bb2121) | Active, not recruiting | USA | CAN | 6 |
NCT03374085 | Phase I | CC-92480 + Dexamethasone | A Safety, PK and Efficacy Study of CC-92480 in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma | Recruiting | USA | CAN | 4 |
NCT03399799 | Phase I | JNJ-64407564 | Dose Escalation Study of JNJ-64407564 in Participants With Relapsed or Refractory Multiple Myeloma | Recruiting | USA | 3 |
NCT03411031 | Phase II | Elotuzumab + Lenalidomide Dexamethasone | Elotuzumab Plus Lenalidomide (Elo/Rev) for Serologic Relapse/Progression While on Lenalidomide | Active, not recruiting | USA | 0 |
NCT03412565 | Phase II | Bortezomib + Daratumumab + Dexamethasone + Melphalan + Prednisone Daratumumab + Dexamethasone + Lenalidomide Bortezomib + Daratumumab + Dexamethasone + Lenalidomide | A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens | Active, not recruiting | USA | 8 |
NCT03424603 | Phase I | STRO-001 | Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies | Recruiting | USA | 0 |
NCT03428373 | Phase II | Dexamethasone + Lenalidomide + Rivaroxaban Aspirin + Dexamethasone + Lenalidomide | ASA vs. Rivaroxaban in Newly Diagnosed or Relapsed and Refractory Multiple Myeloma Patients Treated With Len-Dex Combination Therapy. (RithMM) | Recruiting | CAN | 0 |
NCT03439280 | Phase Ib/II | Dexamethasone + Pomalidomide + TAK-079 TAK-079 | A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Participants With Relapsed/Refractory (r/r) Multiple Myeloma (MM) | Recruiting | USA | 0 |
NCT03441958 | Phase Ib/II | Cyclophosphamide + ECT-001 cord blood cells + Fludarabine + Mycophenolate mofetil + Tacrolimus | ECT-001 (UM171) Expanded Cord Blood Transplant to Treat High-risk Multiple Myeloma | Recruiting | CAN | 0 |
NCT03457142 | Phase II | BMS-188667 + Dexamethasone + Ixazomib | Abatacept, Ixazomib Citrate, and Dexamethasone in Treating Patients With Multiple Myeloma Resistant to Chemotherapy | Recruiting | USA | 0 |
NCT03464916 | Phase I | CAR2 anti-CD38 A2 CAR T cells | Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma Patients | Recruiting | USA | 0 |
NCT03465540 | Phase I | AMG 397 + Azacitidine AMG 397 + Dexamethasone AMG 397 | Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies | Active, not recruiting | USA | 5 |
NCT03477539 | Phase II | Daratumumab + Lenalidomide Daratumumab | Daratumumab in Treating Transplant-Eligible Participants With Multiple Myeloma | Recruiting | USA | 0 |
NCT03480360 | Phase III | Cyclophosphamide + Fludarabine Filgrastim + Mycophenolate mofetil + Tacrolimus | Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression | Recruiting | USA | 0 |
NCT03481556 | Phase Ib/II | Bortezomib + Dexamethasone + Melflufen Daratumumab + Dexamethasone + Melflufen | Study of Melflufen + Dex With Bortezomib or Daratumumab in Patients With RRMM (ANCHOR) | Recruiting | USA | 3 |
NCT03486067 | Phase I | CC-93269 | Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Subjects With Relapsed and Refractory Multiple Myeloma | Recruiting | USA | 4 |
NCT03489525 | Phase I | MEDI2228 | MEDI2228 in Subjects With Relapsed/Refractory Multiple Myeloma (MEDI2228) | Recruiting | USA | 4 |
NCT03492138 | Phase Ib/II | Dexamethasone + Ixazomib + ONC201 | Ixazomib, ONC201, and Dexamethasone in Relapsed/Refractory Multiple Myeloma | Terminated | USA | 0 |
NCT03502577 | Phase I | Anti-BCMA CAR T Cells + Cyclophosphamide + Fludarabine + LY3039478 | BCMA-Specific CAR T-Cells Combined With a Gamma Secretase Inhibitor (JSMD194) to Treat Relapsed or Persistent Multiple Myeloma | Recruiting | USA | 0 |
NCT03506360 | Phase II | Dexamethasone + Ixazomib + Pembrolizumab | Pembrolizumab, Ixazomib Citrate, and Dexamethasone in Treating Participants With Relapsed Multiple Myeloma | Active, not recruiting | USA | 0 |
NCT03506802 | Phase I | Filgrastim + Plerixafor Lenalidomide Aldesleukin + LV-NY-ESO TCR/sr39TK PBSC + RV-NY-ESO TCR PBMC Melphalan | TCR Genetically Engineered PBMC and PBSC After Melphalan Conditioning Regimen in Treating Participants With Relapsed and Refractory Multiple Myeloma | Withdrawn | USA | 0 |
NCT03525678 | Phase II | belantamab mafodotin-blmf | A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Subjects With Multiple Myeloma Who Have Failed Prior Treatment With an Anti-CD38 Antibody | Active, not recruiting | USA | CAN | 6 |
NCT03530683 | Phase I | TTI-622 | A Trial of TTI-622 in Patients With Advanced Relapsed or Refractory Lymphoma or Myeloma | Recruiting | USA | 0 |
NCT03537482 | Phase I | APG-2575 | APG-2575 Study of Safety, Tolerability ,PK/PD in Patients With Hematologic Malignancies | Recruiting | USA | 1 |
NCT03539744 | Phase III | Dexamethasone + Pomalidomide Dexamethasone + Venetoclax | A Study of Venetoclax and Dexamethasone Compared With Pomalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (CANOVA) | Recruiting | USA | CAN | 18 |
NCT03544281 | Phase II | belantamab mafodotin-blmf + Bortezomib + Dexamethasone belantamab mafodotin-blmf + Dexamethasone + Lenalidomide | To Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-drug Conjugate, GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or in Combination With Bortezomib Plus Dexamethasone (Arm B) in Subjects With Relapsed/Refractory Multiple Myeloma (RRMM) | Recruiting | USA | CAN | 4 |
NCT03548207 | Phase Ib/II | JNJ-68284528 | A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple Myeloma | Active, not recruiting | USA | 1 |
NCT03567616 | Phase II | Dexamethasone + Pomalidomide + Venetoclax | A Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma | Completed | USA | 2 |
NCT03582033 | Phase I | SEA-BCMA | A Safety Study of SEA-BCMA in Patients With Multiple Myeloma | Recruiting | USA | 0 |
NCT03591614 | Phase I | DKK1 dendritic cell vaccine | Dendritic Cell DKK1 Vaccine for Monoclonal Gammopathy and Stable or Smoldering Myeloma | Not yet recruiting | USA | 0 |
NCT03601078 | Phase II | bb2121 | An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma Having Progressed Within One Year of Initial Treatment (KarMMa-2) | Recruiting | USA | 5 |
NCT03602612 | Phase I | Anti-BCMA CAR T Cells + Cyclophosphamide + Fludarabine | T Cells Expressing a Novel Fully-Human Anti-BCMA CAR for Treating Multiple Myeloma | Recruiting | USA | 0 |
NCT03605719 | Phase I | Carfilzomib + Dexamethasone + Nivolumab + Pelareorep Carfilzomib + Dexamethasone + Nivolumab | Dexamethasone, Carfilzomib, & Nivolumab With Reovirus for Relapsed/Refractory Multiple Myeloma | Recruiting | USA | 0 |
NCT03607643 | Phase Ib/II | Temozolomide Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Bevacizumab + Cannabidiol + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Bortezomib Bortezomib + Cannabidiol Cannabidiol + Gemcitabine Cannabidiol + Temozolomide Gemcitabine | A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies | Unknown status | USA | 0 |
NCT03622775 | Phase II | Daratumumab | Daratumumab in Treating Participants With Relapsed Multiple Myeloma After Stem Cell Transplant | Recruiting | USA | 0 |
NCT03634800 | Phase II | Nivolumab | Radiotherapy With Immunotherapy for Systemic Effect in Myeloma (RISE-M) (RISE-M) | Active, not recruiting | USA | 0 |
NCT03650491 | Phase I | FOR46 | A Study of FOR46 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) | Recruiting | USA | 0 |
NCT03651128 | Phase III | Bortezomib + Daratumumab + Dexamethasone bb2121 Dexamethasone + Ixazomib + Lenalidomide Daratumumab + Dexamethasone + Pomalidomide | Efficacy and Safety Study of bb2121 Versus Standard Triplet Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) (KarMMa-3) | Recruiting | USA | CAN | 9 |
NCT03652064 | Phase III | Bortezomib + Dexamethasone + Lenalidomide Bortezomib + Daratumumab + Dexamethasone + Lenalidomide Dexamethasone + Lenalidomide Daratumumab + Dexamethasone + Lenalidomide | A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy | Active, not recruiting | USA | CAN | 11 |
NCT03657420 | Phase I | Dexamethasone + Nab-Rapamycin + Pomalidomide | Safety and Efficacy of ABI-009 (Nab-rapamycin) in Combination With Pomalidomide and Dexamethasone for Relapsed and Refractory Multiple Myeloma | Withdrawn | USA | 0 |
NCT03672318 | Phase I | ATLCAR.CD138 + Cyclophosphamide + Fludarabine | Study of ATLCAR.CD138 Cells for Relapsed/Refractory Multiple Myeloma | Recruiting | USA | 0 |
NCT03687125 | Phase Ib/II | Tinostamustine | Tinostamustine Conditioning and Autologous Stem Cell (TITANIUM1) | Terminated | USA | 2 |
NCT03701321 | Phase Ib/II | Bortezomib + Daratumumab + Dexamethasone Bortezomib + Daratumumab + Dexamethasone + Venetoclax | Daratumumab, Bortezomib, and Dexamethasone With or Without Venetoclax in Treating Patients With Relapsed or Refractory Multiple Myeloma | Withdrawn | USA | 0 |
NCT03702725 | Phase I | Dexamethasone + Ibrutinib + Lenalidomide | Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma | Recruiting | USA | 0 |
NCT03710421 | Phase I | CS1-CAR T cells + Cyclophosphamide + Fludarabine | CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory CS1 Positive Multiple Myeloma | Recruiting | USA | 0 |
NCT03713294 | Phase II | Dexamethasone + Elotuzumab + Pomalidomide | Dexamethasone, Elotuzumab, and Pomalidomide in Treating Patients With Refractory Multiple Myeloma | Recruiting | USA | 0 |
NCT03715478 | Phase Ib/II | belantamab mafodotin-blmf + Dexamethasone + Pomalidomide | Multi-Center Study of GSK2857916 in Combination With Pomalidomide and Dex | Recruiting | CAN | 0 |
NCT03729804 | Phase III | Bortezomib + Dexamethasone + Lenalidomide Carfilzomib + Dexamethasone + Lenalidomide | Carfilzomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone (KRd vs. VRd) in Patients With Newly Diagnosed Multiple Myeloma (COBRA) ((COBRA)) | Recruiting | USA | 0 |
NCT03732703 | Phase Ib/II | Dexamethasone + Enasidenib + Ixazomib + Pomalidomide Cobimetinib + Dexamethasone + Ixazomib + Pomalidomide Dexamethasone + Erdafitinib + Ixazomib + Pomalidomide Dexamethasone + Ixazomib + Pomalidomide + Venetoclax Abemaciclib + Dexamethasone + Ixazomib + Pomalidomide Daratumumab + Dexamethasone + Ixazomib + Pomalidomide | Myeloma-Developing Regimens Using Genomics (MyDRUG) (MyDRUG) | Recruiting | USA | 0 |
NCT03741127 | Phase I | Rimiducid | Long-Term Follow-Up Study for Subjects Treated With P-BCMA-101 | Enrolling by invitation | USA | 0 |
NCT03761108 | Phase Ib/II | REGN5458 | First in Human (FIH) Study of REGN5458 in Patients With Relapsed or Refractory Multiple Myeloma | Recruiting | USA | 1 |
NCT03763162 | Phase II | Bortezomib + Daratumumab + Dexamethasone Daratumumab + Dexamethasone + Ixazomib | Daratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma | Recruiting | USA | 0 |
NCT03770260 | Phase I | Ixazomib + MLN4924 | Ixazomib and Pevonedistat in Treating Patients With Multiple Myeloma That Has Come Back or Does Not Respond to Treatment | Recruiting | USA | 0 |
NCT03773107 | Phase Ib/II | Carfilzomib + Dexamethasone + Ruxolitinib | LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for Carfilzomib-Refractory Multiple Myeloma | Recruiting | USA | 0 |
NCT03782064 | Phase II | DC myeloma fusion vaccine + Nivolumab | Dendritic Cell (DC)/Myeloma Fusions in Combination With Nivolumab in Patients With Relapsed Multiple Myeloma | Active, not recruiting | USA | 0 |
NCT03785184 | Phase II | Dexamethasone + Lenalidomide + Venetoclax | A Study of Venetoclax Plus Lenalidomide and Dexamethasone for the Treatment of Newly Diagnosed t(11;14)-Positive Multiple Myeloma in Subjects Who Are Ineligible for High-Dose Therapy | Withdrawn | USA | CAN | 2 |
NCT03829020 | Phase I | Metformin + Nelfinavir Bortezomib + Metformin + Nelfinavir | Metformin and Nelfinavir in Treating Patients With Relapsed and/or Refractory Multiple Myeloma | Recruiting | USA | 0 |
NCT03837509 | Phase Ib/II | Daratumumab + INCB001158 Daratumumab | INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma | Recruiting | USA | 2 |
NCT03841565 | Phase II | Daratumumab + Dexamethasone + Pomalidomide | Daratumumab, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma | Recruiting | USA | 0 |
NCT03848845 | Phase II | belantamab mafodotin-blmf + Pembrolizumab | Study Evaluating Safety, Tolerability and Clinical Activity of GSK2857916 in Combination With Pembrolizumab in Subjects With Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 4) | Active, not recruiting | USA | CAN | 2 |
NCT03901963 | Phase III | Daratumumab + Lenalidomide Lenalidomide | A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant (AURIGA) | Recruiting | USA | 0 |
NCT03910439 | Phase II | Avelumab | Avelumab in Combination With Hypofractionated Radiotherapy in Patients With Relapsed Refractory Multiple Myeloma | Terminated | USA | 0 |
NCT03915184 | Phase I | Anti-BCMA CAR T Cells | Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma | Recruiting | USA | CAN | 0 |
NCT03933735 | Phase I | TNB-383B | A Study of TNB-383B in Subjects With Relapsed or Refractory Multiple Myeloma | Recruiting | USA | 0 |
NCT03937635 | Phase III | Dexamethasone + Lenalidomide Daratumumab + Dexamethasone + Lenalidomide | Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma | Recruiting | USA | 0 |
NCT03942224 | Phase II | Daratumumab + Dexamethasone + Ixazomib Bortezomib + Daratumumab + Dexamethasone | Daratumumab, Ixazomib, & Dexamethasone With or Without Bortezomib in Patients With Newly Diagnosed Multiple Myeloma (DeRIVE) | Recruiting | USA | 0 |
NCT03958656 | Phase I | Anti-SLAMF7 CAR T cells + Cyclophosphamide + Fludarabine Rimiducid | T-cells Expressing an Anti-SLAMF7 CAR for Treating Multiple Myeloma | Completed | USA | 0 |
NCT03984097 | Phase I | Dexamethasone + Lenalidomide + TAK-079 Bortezomib + Dexamethasone + Lenalidomide + TAK-079 | A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM) | Recruiting | USA | 0 |
NCT03989414 | Phase Ib/II | Bortezomib + CC-92480 + Dexamethasone CC-92480 + Daratumumab + Dexamethasone Carfilzomib + CC-92480 + Dexamethasone | A Study to Determine the Recommended Dose and Regimen and Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM) | Recruiting | USA | CAN | 7 |
NCT03997968 | Phase Ib/II | CYT01B | A Phase 1/2 Study of CYT-0851, an Oral RAD51 Inhibitor, in B-Cell Malignancies and Advanced Solid Tumors | Recruiting | USA | 0 |
NCT04000282 | Phase I | SAR442085 | First-in-human Single Agent Study of SAR442085 in Relapsed or Refractory Multiple Myeloma | Recruiting | USA | 4 |
NCT04017130 | Phase I | TAK-169 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Efficacy of TAK-169 in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) | Recruiting | USA | 0 |
NCT04036461 | Phase I | CC-99712 | A Study of CC-99712, a BCMA Antibody-Drug Conjugate, in Subjects With Relapsed and Refractory Multiple Myeloma | Recruiting | USA | CAN | 0 |
NCT04045028 | Phase I | MTIG7192A Daratumumab + MTIG7192A MTIG7192A + Rituximab | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | Recruiting | USA | 1 |
NCT04045795 | Phase I | Dexamethasone + Isatuximab + Pomalidomide | Multi-center, Open-label, Phase 1b Study in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) | Recruiting | USA | 4 |
NCT04052880 | Phase II | Daratumumab + Ixazomib Bortezomib + Daratumumab + Dexamethasone + Lenalidomide Daratumumab + Lenalidomide | Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly NDMM | Recruiting | USA | 0 |
NCT04071457 | Phase III | Daratumumab + Lenalidomide + rHuPH20 Lenalidomide | S1803, Daratumumab/rHuPh20 +/- Lenalidomide as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration (DRAMMATIC) | Recruiting | USA | 0 |
NCT04083534 | Phase I | REGN5459 | First In Human (FIH) Study of REGN5459 in Patients With Relapsed or Refractory Multiple Myeloma (MM) | Recruiting | USA | 0 |
NCT04083898 | Phase Ib/II | Bendamustine + Isatuximab + Prednisone | Isatuximab, Bendamustine, and Prednisone in Penta-Refractory Multiple Myeloma | Recruiting | USA | 0 |
NCT04091126 | Phase III | Bortezomib + Dexamethasone + Lenalidomide belantamab mafodotin-blmf + Bortezomib + Dexamethasone + Lenalidomide | Bortezomib, Lenalidomide and Dexamethasone (VRd) With Belantamab Mafodotin Versus VRd Alone in Transplant Ineligible Multiple Myeloma | Recruiting | USA | CAN | 7 |
NCT04093596 | Phase I | ALLO-647 + ALLO-715 ALLO-647 + ALLO-715 + Cyclophosphamide + Fludarabine | Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma (UNIVERSAL) (UNIVERSAL) | Recruiting | USA | 0 |
NCT04108195 | Phase I | Daratumumab + JNJ-64007957 Daratumumab + JNJ-64407564 | A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma | Recruiting | USA | CAN | 3 |
NCT04111107 | Phase II | Precision Medicine for Patients With Identified Actionable Mutations | Recruiting | USA | 0 | |
NCT04119336 | Phase II | Cyclophosphamide + Dexamethasone + Ixazomib + Nivolumab | Nivolumab, Ixazomib, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Myeloma | Active, not recruiting | USA | 0 |
NCT04123418 | Phase I | WVT078 | A Study of WVT078 in Patients With Multiple Myeloma (MM) | Recruiting | USA | 7 |
NCT04126200 | Phase II | belantamab mafodotin-blmf + GSK3359609 belantamab mafodotin-blmf belantamab mafodotin-blmf + GSK3174998 | Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 5) | Recruiting | USA | CAN | 7 |
NCT04133636 | Phase II | JNJ-68284528 | A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma (CARTITUDE-2) | Recruiting | USA | 6 |
NCT04136756 | Phase I | NKTR-255 Daratumumab + NKTR-255 | NKTR-255 in Relapsed/Refractory Multiple Myeloma and Non Hodgkin Lymphoma and Combined With Daratumumab for Multiple Myeloma | Recruiting | USA | 0 |
NCT04140162 | Phase II | Lenalidomide Bortezomib + Daratumumab + Dexamethasone + Lenalidomide Daratumumab + Dexamethasone + Lenalidomide Daratumumab + Lenalidomide | Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma With Upfront Daratumumab-based Therapy | Recruiting | USA | 0 |
NCT04142619 | Phase I | UCARTCS1A | Study Evaluating Safety and Efficacy of UCART Targeting CS1 in Patients With Relapsed/Refractory Multiple Myeloma (MELANI-01) | Recruiting | USA | 0 |
NCT04150692 | Phase II | Daratumumab | Escalation of Daratumumab Frequency Following Biochemical Progression in Relapsed/Refractory Multiple Myeloma | Recruiting | USA | 0 |
NCT04150965 | Phase Ib/II | Relatlimab BMS-986207 BMS-986207 + Dexamethasone + Pomalidomide Dexamethasone + Pomalidomide + Relatlimab Dexamethasone + Elotuzumab + Pomalidomide | Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT | Recruiting | USA | 0 |
NCT04151667 | Phase II | Daratumumab + Dexamethasone Bortezomib + Daratumumab + Dexamethasone Daratumumab + Dexamethasone + Lenalidomide | Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple Myeloma | Recruiting | USA | 0 |
NCT04162210 | Phase III | Dexamethasone + Pomalidomide belantamab mafodotin-blmf | Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) | Recruiting | USA | CAN | 16 |
NCT04176380 | Phase II | RAPA-201 T cells | RAPA-201 T Cell Therapy for Relapsed, Refractory Multiple Myeloma | Recruiting | USA | 0 |
NCT04178902 | Phase I | ABBV-467 | A Study of the Safety and Tolerability of ABBV-467 in Adult Participants With Relapsed/Refractory Multiple Myeloma | Recruiting | USA | 6 |
NCT04181827 | Phase III | Daratumumab + Dexamethasone + Pomalidomide Bortezomib + Dexamethasone + Pomalidomide Bortezomib + Cyclophosphamide + Dexamethasone + Fludarabine + JNJ-68284528 + Pomalidomide Cyclophosphamide + Daratumumab + Dexamethasone + Fludarabine + JNJ-68284528 + Pomalidomide | A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma (CARTITUDE-4) | Recruiting | USA | 16 |
NCT04184050 | Phase Ib/II | HPN217 | A Phase 1/2 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and PK of HPN217 in Patients With R/R MM | Recruiting | USA | 1 |
NCT04196491 | Phase I | Lenalidomide bb2121 + Cyclophosphamide + Fludarabine | A Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (NDMM) (KarMMa-4) (KarMMa-4) | Recruiting | USA | 0 |
NCT04205240 | Phase II | Cyclophosphamide + Daratumumab + Mycophenolate mofetil + Tacrolimus Fludarabine + Melphalan | Reduce Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed Multiple Myeloma | Recruiting | USA | 0 |
NCT04205409 | Phase II | Nivolumab | Nivolumab for the Treatment of Relapsed or Refractory Hematologic Malignancies | Recruiting | USA | 0 |
NCT04214093 | Phase I | AZD0466 | A Study of AZD0466 in Patients With Advanced Hematologic or Solid Tumors | Recruiting | USA | 0 |
NCT04244656 | Phase I | CTX120 | A Safety and Efficacy Study Evaluating CTX120 in Subjects With Relapsed or Refractory Multiple Myeloma | Recruiting | USA | CAN | 2 |
NCT04246047 | Phase III | belantamab mafodotin-blmf + Bortezomib + Dexamethasone Bortezomib + Daratumumab + Dexamethasone | Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma (DREAMM 7) | Recruiting | USA | CAN | 13 |
NCT04268199 | Phase II | Bortezomib | A Multicentre, Non-Blinded Study Exploring Self-Administration of Chemotherapy in the Home Environment (EASE) | Recruiting | CAN | 0 |
NCT04268498 | Phase II | Carfilzomib + Dexamethasone + Lenalidomide Bortezomib + Dexamethasone + Lenalidomide Carfilzomib + Daratumumab + Dexamethasone + Lenalidomide | A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma | Recruiting | USA | 1 |
NCT04280328 | Phase I | CPI-444 + Daratumumab CPI-444 | Study of CPI-444 as a Single Agent and in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma | Recruiting | USA | 0 |
NCT04283097 | Phase I | KPG-818 | Safety, Tolerability and Pharmacokinetics Study of KPG-818 in Hematological Malignancies Subjects | Recruiting | USA | 0 |
NCT04309084 | Phase Ib/II | CYNK-001 | Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma | Recruiting | USA | 0 |
NCT04352205 | Phase II | Bortezomib + Daratumumab + Dexamethasone + Lenalidomide Bortezomib + Daratumumab + Dexamethasone + Thalidomide | Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure | Recruiting | USA | 0 |
NCT04394650 | Phase I | Cyclophosphamide + Fludarabine CC-98633 | A Study of CC-98633, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed and/or Refractory Multiple Myeloma | Recruiting | USA | 0 |
NCT04405167 | Phase I | Tasquinimod Dexamethasone + Ixazomib + Lenalidomide + Tasquinimod | Tasquinimod for the Treatment of Relapsed or Refractory Myeloma | Recruiting | USA | 0 |
NCT04430894 | Phase II | Carfilzomib + Dexamethasone + Isatuximab + Lenalidomide Carfilzomib + Isatuximab + Lenalidomide Lenalidomide | KRDI in Transplant-Eligible MM | Recruiting | USA | 0 |
NCT04445701 | Phase Ib/II | AO-176 AO-176 + Dexamethasone AO-176 + Bortezomib + Dexamethasone | Study of AO-176 as Monotherapy and in Combination With Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma | Recruiting | USA | 0 |
NCT04453397 | Expanded access | TNB-383B | Expanded Access for TNB-383B in a Subject With Relapsed/Refractory Multiple Myeloma | No longer available | USA | 0 |
NCT04484623 | Phase III | Bortezomib + Dexamethasone + Pomalidomide belantamab mafodotin-blmf + Dexamethasone + Pomalidomide | Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma (DREAMM 8) | Recruiting | USA | 5 |
NCT04505813 | Phase Ib/II | NEXI-002 T Cells | Antigen-specific T Cell Therapy for Patients With Relapsed Refractory Multiple Myeloma | Recruiting | USA | 0 |
NCT04519476 | Phase I | Lenalidomide + Selinexor Methylprednisolone | Selinexor Treatment for Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy. | Recruiting | USA | 0 |
NCT04534322 | Expanded access | Dexamethasone + Melflufen | Expanded Access Program for Melphalan Flufenamide (Melflufen) in Triple Class Refractory Multiple Myeloma (sEAPort) | Available | USA | 0 |
NCT04543305 | Phase I | PRT1419 | A Study of PRT1419 in Patients With Relapsed/Refractory Hematologic Malignancies | Recruiting | USA | 0 |
NCT04555551 | Phase I | MCARH109 | MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma | Recruiting | USA | 0 |
NCT04557098 | Phase II | JNJ-64007957 | A Study of Teclistamab, in Participants With Relapsed or Refractory Multiple Myeloma | Recruiting | USA | CAN | 8 |
NCT04566328 | Phase III | Bortezomib + Daratumumab + Dexamethasone + Lenalidomide Daratumumab + Lenalidomide Daratumumab + Dexamethasone + Lenalidomide | Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial | Recruiting | USA | 0 |
NCT04570631 | Phase I | ABBV-621 + Bortezomib + Dexamethasone | Study to Determine Recommended Phase 2 Dose of Intravenous (IV) Eftozanermin Alfa in Combination With IV or Subcutaneous (SC) Bortezomib and Oral Dexamethasone Tablet and to Assess Change in Disease Symptoms in Adult Participants With Relapsed or Refractory Multiple Myeloma | Recruiting | USA | 5 |
NCT04586426 | Phase I | JNJ-64007957 + JNJ-64407564 | A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma | Recruiting | CAN | 3 |
NCT04614636 | Phase I | Cyclophosphamide + Fludarabine Daratumumab + FT538 Elotuzumab + FT538 FT538 | FT538 in Subjects With Advanced Hematologic Malignancies | Recruiting | USA | 0 |
NCT04634552 | Phase II | JNJ-64407564 | A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma | Recruiting | USA | 8 |
NCT04635735 | Phase Ib/II | Ipilimumab | Study of Ipilimumab After Stem Cell Transplantation in People With Relapsed/Refractory Multiple Myeloma | Recruiting | USA | 0 |
NCT04643002 | Phase Ib/II | Dexamethasone + Isatuximab + Pomalidomide Dexamethasone + Isatuximab + SAR439459 | Isatuximab in Combination With Novel Agents in RRMM | Recruiting | USA | 2 |
NCT04649359 | Phase II | PF-06863135 | Study of PF-06863135 Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb | Recruiting | USA | 0 |
NCT04653246 | Phase II | Bortezomib + Dexamethasone + Isatuximab + Lenalidomide | Phase 2, Multi-Center, Single-Arm, Open-Label Study to Evaluate the Efficacy and Safety of the Combination Regimen Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma | Not yet recruiting | USA | 0 |
NCT04661137 | Phase II | Dexamethasone + Pomalidomide + Selinexor Daratumumab + Dexamethasone + Selinexor Carfilzomib + Dexamethasone + Selinexor | A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma | Not yet recruiting | USA | 0 |
NCT04722146 | Phase I | JNJ-64007957 + PF-03084014 Daratumumab + JNJ-64007957 + Pomalidomide Bortezomib + Daratumumab + JNJ-64007957 + Lenalidomide | A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma | Recruiting | USA | 3 |
NCT04756401 | Phase II | Carfilzomib + Daratumumab + Dexamethasone + Selinexor | Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple Myeloma | Not yet recruiting | USA | 0 |
NCT04764942 | Phase Ib/II | Dexamethasone + Pomalidomide + Selinexor Carfilzomib + Dexamethasone + Pomalidomide + Selinexor | Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE Trial | Not yet recruiting | USA | 0 |
NCT04772989 | Phase I | A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies | Not yet recruiting | USA | 0 | |
NCT04775550 | Lenalidomide Bortezomib Dexamethasone Daratumumab | DARA RVD For High Risk SMM | Not yet recruiting | USA | 0 |